Related references
Note: Only part of the references are listed.PTPRO-related CD8+ T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
Hongmei Dong et al.
FRONTIERS IN IMMUNOLOGY (2022)
Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles
Xiao Xiong et al.
JOURNAL OF EXTRACELLULAR VESICLES (2022)
Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration
Hongmei Dong et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target
Xiao Xiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma
Jinfeng Gan et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis
Lu Wang et al.
CANCER LETTERS (2019)
Systems Biology of Cancer Metastasis
Yasir Suhail et al.
CELL SYSTEMS (2019)
Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer
Ling Lim et al.
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2019)
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega et al.
CANCER DISCOVERY (2019)
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Simon Baldacci et al.
LUNG CANCER (2018)
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Paolo M. Comoglio et al.
NATURE REVIEWS CANCER (2018)
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
H. Dong et al.
ONCOGENE (2017)
Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis
Hongmei Dong et al.
JOURNAL OF PATHOLOGY (2017)
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Samuel J. Klempner et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Puyu Shi et al.
CANCER LETTERS (2016)
Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling
Eunice Yuen Ting Lau et al.
CELL REPORTS (2016)
c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target
Yohei Ozawa et al.
BMC CANCER (2015)
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Juan Madoz-Gurpide et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma
Liping Liu et al.
GUT (2015)
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
J. S. Ross et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling
Y. Feng et al.
CELL DEATH & DISEASE (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
Hiroaki Kato et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Substrate Specificity of R3 Receptor-like Protein-tyrosine Phosphatase Subfamily toward Receptor Protein-tyrosine Kinases
Juichi Sakuraba et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy
Yi-Teng Huang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients
Yan-Jie You et al.
CANCER LETTERS (2012)
The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype
Francesca De Bacco et al.
CANCER RESEARCH (2012)
Expression Profiling during Mammary Epithelial Cell Three-Dimensional Morphogenesis Identifies PTPRO as a Novel Regulator of Morphogenesis and ErbB2-Mediated Transformation
Min Yu et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
E. Arriola et al.
BRITISH JOURNAL OF CANCER (2011)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
Tingting Sun et al.
CELL (2011)
Inside the human cancer tyrosine phosphatome
Sofi G. Julien et al.
NATURE REVIEWS CANCER (2011)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers
Pirus Ghadjar et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies
Shingo Miyamoto et al.
CARCINOGENESIS (2008)
Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase
Veena Sangwan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
被撤回的出版物: Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer (Retracted article. See vol. 119, 2022)
T Motiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice
XH Tang et al.
CLINICAL CANCER RESEARCH (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas
T Motiwala et al.
ONCOGENE (2003)